603259 药明康德 Deep Research

当前结论

Research conclusion: 继续观察.
Trade conclusion: 等确认.
Data trade date: 20260721; final status: PASS_WITH_LIMITATIONS; outbound/order permission: NO.

较上一交易日变化

This report uses one frozen shared analysis result; change classification is based on the current controlled evidence snapshot.

评分、风险等级和交易定位

Core data gate=PASS; report completeness=PASS_WITH_LIMITATIONS; research priority=B-.

公司和主营业务画像

公司=药明康德; 证券代码=603259.SH; 板块=SH_MAIN；市场=主板。
行业=化学制药；主营分部=其他业务、化学业务(产品)、测试业务、生物学业务(产品)、终止经营业务；产品/服务=其他业务, 化学业务(产品), 测试业务, 生物学业务(产品), 终止经营业务。
商业模式=化学制药；产业链定位=化学制药相关的其他业务、化学业务(产品)、测试业务、生物学业务(产品)、终止经营业务业务环节；收入构成状态=DISCLOSED_FINA_MAINBZ。
上市日期=20180508；上市年限=8.2；信息完整性=COMPLETE。
业务标签=创新药, 医药；数据来源=stock_basic, fina_mainbz。

主营业务与收入结构

其他业务: revenue=236100794.68; profit=202290365.70.
化学业务(产品): revenue=36465846882.97; profit=18923311101.43.
测试业务: revenue=4041701030.67; profit=1182442410.90.
生物学业务(产品): revenue=2677175030.51; profit=927848801.93.
终止经营业务: revenue=2035342035.35; profit=418838536.28.

多期财务趋势

Annual series (ANNUAL):
20251231: revenue=45456165774.18; revenue_yoy=15.84%; parent_net_profit=19150582400.69; parent_net_profit_yoy=102.65%; deduct_profit=13240556954.42; gross_margin=47.64%; net_margin=42.53%; ROE=27.69%; OCF=17203161622.00.
20241231: revenue=39241431359.88; revenue_yoy=-2.73%; parent_net_profit=9450308427.78; parent_net_profit_yoy=-1.63%; deduct_profit=9988102785.24; gross_margin=41.48%; net_margin=24.38%; ROE=16.62%; OCF=12406514834.59.
20231231: revenue=40340806877.04; revenue_yoy=2.51%; parent_net_profit=9606749135.07; parent_net_profit_yoy=9.00%; deduct_profit=9747587804.59; gross_margin=41.18%; net_margin=24.05%; ROE=18.89%; OCF=13386911778.77.
20221231: revenue=39354777805.53; revenue_yoy=71.84%; parent_net_profit=8813713033.51; parent_net_profit_yoy=72.91%; deduct_profit=NOT_AVAILABLE (controlled source unavailable); gross_margin=NOT_AVAILABLE (controlled source unavailable); net_margin=NOT_AVAILABLE (controlled source unavailable); ROE=NOT_AVAILABLE (controlled source unavailable); OCF=10616029916.68.
20211231: revenue=22902385129.11; revenue_yoy=38.50%; parent_net_profit=5097155283.68; parent_net_profit_yoy=72.19%; deduct_profit=4063633174.64; gross_margin=36.28%; net_margin=22.43%; ROE=14.36%; OCF=4589288733.11.
Quarterly series (QUARTERLY_CUMULATIVE and SINGLE_QUARTER):
20260331 cumulative: revenue=12435776568.29; parent_net_profit=4651517987.76; single_quarter_revenue=12435776568.29; single_quarter_parent_net_profit=4651517987.76.
20250930 cumulative: revenue=32856716508.86; parent_net_profit=12075512956.92; single_quarter_revenue=12057434626.40; single_quarter_parent_net_profit=3514630329.36.
20250630 cumulative: revenue=20799281882.46; parent_net_profit=8560882627.56; single_quarter_revenue=11144686578.18; single_quarter_parent_net_profit=4888921677.09.
20250331 cumulative: revenue=9654595304.28; parent_net_profit=3671960950.47; single_quarter_revenue=9654595304.28; single_quarter_parent_net_profit=3671960950.47.
20240930 cumulative: revenue=27702002254.76; parent_net_profit=6532934698.28; single_quarter_revenue=10461083991.74; single_quarter_parent_net_profit=2293112685.17.
20240630 cumulative: revenue=17240918263.02; parent_net_profit=4239822013.11; single_quarter_revenue=9258984026.06; single_quarter_parent_net_profit=2297611319.46.
20240331 cumulative: revenue=7981934236.96; parent_net_profit=1942210693.65; single_quarter_revenue=7981934236.96; single_quarter_parent_net_profit=1942210693.65.
20230930 cumulative: revenue=29541326133.58; parent_net_profit=8076407160.91; single_quarter_revenue=10670040635.96; single_quarter_parent_net_profit=2763287456.82.

盈利能力

Gross margin trend=UP; net margin trend=UP; ROE trend=UP; deduct profit ratio=NOT_AVAILABLE (controlled source unavailable); non-recurring effect=NOT_AVAILABLE (controlled source unavailable).
Limitation: interface=DARB statement field:deducted profit; periods=20260331; impact=deducted profit quality conclusion is limited; blocks_module=NO.

现金流与资产质量

OCF/parent profit=0.77; inventory growth=84.56%; receivable growth=-3.15%.
Inventory=9965880371.58; receivables=7700936967.37; debt ratio=21.08%; interest-bearing debt=NOT_AVAILABLE (controlled source unavailable); cash coverage=NOT_AVAILABLE (controlled source unavailable).
Limitation: interface=DARB statement field:interest-bearing debt; periods=20260331; impact=interest-bearing debt quality conclusion is limited; blocks_module=NO.

估值分析

PE_TTM_ACTUAL=19.70multiple; PE_STATIC_LATEST_ANNUAL=19.70multiple; PE_FORWARD_FORECAST=NOT_AVAILABLE (NO_STRUCTURED_FORECAST_PROFIT); PB_LATEST=4.73multiple; PS_TTM=8.30multiple.
VALUATION_INTERNAL_CONFLICT_COUNT=0; forward forecast is never labelled as actual TTM.
Limitation: interface=structured forecast profit/PE; periods=none; impact=forward PE is intentionally not substituted for actual TTM PE; blocks_module=NO.

估值情景

CURRENT_PROFIT: premise=latest actual TTM profit; PE sensitivity=19.70multiple; actual-TTM-only=YES.
NORMALIZED_PROFIT: premise=actual TTM profit normalized only as sensitivity, not a forecast; PE sensitivity=17.13multiple; actual-TTM-only=YES.
CYCLE_DOWNTURN_PROFIT: premise=actual TTM profit stress sensitivity, not a forecast; PE sensitivity=28.15multiple; actual-TTM-only=YES.

基本面核心矛盾

Bear case / counterevidence: 药明康德: 药明康德 risk context: 交易风险：短线趋势；若资金与价格继续分歧，交易动作维持观察。 occurs or the structured technical/fundamental invalidation condition is met..

行业与主线

Industry=PHARMA_CORE; cycle drivers=创新药, 医药.

直接同行对比

DIRECT_PEER_UNIVERSE:
国药一致: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
ST海王: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
丰原药业: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
派林生物: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
英特集团: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
丽珠集团: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
四环生物: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
万泽股份: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
海南海药: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
东北制药: comparability=1.0; match=existing controlled core_peer_set selected by the shared industry/business profile; mismatch=none.
EXTENDED_PEER_UNIVERSE:
No extended peer context is available.

技术面

bars=320/250; trend=UPTREND; close=124.22; MA5/10/20/60/120=125.62/122.64/121.39/108.79/103.21.
20/60/120/250-day high=135.17/135.17/135.17/135.17; low=105.76/88.32/87.09/68.90.
drawdown=-8.10%; volume_percentile=89.60%; RSI14=49.75; ATR14=7.24; volatility20=3.99%.
support=105.76; resistance=135.17.

资金流和市场情绪

| Date | Pct change | Turnover | Main net amount | Main net / turnover | |---|---:|---:|---:|---:| | 20260721 | 1.80% | 8016853.07 | 8553.76 | 0.11% |

1/3/5/10/20-day main net amount: 8553.76 / NOT_AVAILABLE (controlled source unavailable) / NOT_AVAILABLE (controlled source unavailable) / NOT_AVAILABLE (controlled source unavailable) / NOT_AVAILABLE (controlled source unavailable).
Limitation: interface=local moneyflow cache; periods=20260721; impact=ten-day fund-flow table is partial; blocks_module=NO.
Limitation: interface=local moneyflow cache; periods=20260721; impact=20-day moneyflow aggregate is unavailable; blocks_module=NO.

龙虎榜

No independent Dragon Tiger List conclusion is used unless a structured source is present.

事件与公告证据

No structured announcement item is available.
Limitation: interface=structured announcement/evidence chain; periods=none; impact=no dated verified announcement is used as an event conclusion; blocks_module=NO.

催化与验证点

catalyst=创新药; validation_time=NEXT_DISCLOSURE_OR_OPERATING_DATA; validation_data=company disclosure or audited operating/financial data; conditions=named industry driver improves or remains verified; invalidation=named industry driver weakens or lacks verified evidence.
catalyst=医药; validation_time=NEXT_DISCLOSURE_OR_OPERATING_DATA; validation_data=company disclosure or audited operating/financial data; conditions=named industry driver improves or remains verified; invalidation=named industry driver weakens or lacks verified evidence.

风险与反证

药明康德 risk context: 交易风险：短线趋势；若资金与价格继续分歧，交易动作维持观察。
药明康德 risk context: 行业风险：板块强度和核心股表现必须与 peer_universe_id 同口径复核。
药明康德 risk context: 估值风险：估值样本不足时不输出强判断
药明康德 risk context: 事件证伪风险：财务数据更新需要公告标题、披露日、公告日和报告期补齐后复核。

情景推演

Bull case=药明康德: 创新药 improves and controlled financial/market evidence remains aligned.; base case=药明康德: 创新药 remains within the latest controlled evidence range; continue observation only.; bear case=药明康德: 药明康德 risk context: 交易风险：短线趋势；若资金与价格继续分歧，交易动作维持观察。 occurs or the structured technical/fundamental invalidation condition is met..

交易计划与观察纪律

Consider only if: price: close and MA60 structure are source-valid; fund: 10-day moneyflow table and aggregate direction remain consistent; fundamental: financial history and valuation inputs remain source-traceable; event: dated verified announcement is absent or remains consistent with the evidence snapshot. Invalidation: 短线回补但持续性不足；趋势修复初步成立，重点看回踩 MA5/MA10 不破.

仓位与执行约束

Research output only. It does not send, publish, trade, connect to a broker, or place orders.

数据状态

CORE_DATA_GATE=PASS; FINANCIAL_ANALYSIS_GATE=PASS; VALUATION_GATE=PASS; TECHNICAL_GATE=PASS; FUND_FLOW_GATE=PASS_WITH_LIMITATIONS; EVENT_EVIDENCE_GATE=NOT_APPLICABLE; REPORT_COMPLETENESS_GATE=PASS_WITH_LIMITATIONS; FINAL_REPORT_STATUS=PASS_WITH_LIMITATIONS.

一句话总结

药明康德: research status=PASS_WITH_LIMITATIONS; continue only under the structured evidence and invalidation conditions above.

免责声明

Automated research support only; not investment advice and never an instruction to transact.

603259_药明康德_20260722